{"chunk_id": "WHO_GUIDELINES(TRAIN DATA)__chunk_1257", "source": "WHO_GUIDELINES(TRAIN DATA)", "text": "chanisms for the setting (ANC vs other)\n• Stigma associated with ARV use\n• Potential social harms to pregnant women, including IPV \n• Pending evidence from the National Institute of Child Health and Human Development (NICHD) study on safety and feasibility of PrEP in pregnancy\n• Additional research recommended by WHO and others\n• Cost and frequency of stock-outs – distribution of drug for treatment vs PrEP\nD. Interventions for common physiological symptoms\nD.1–6 • Cultural norms around treatment"}